JPWO2019197675A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019197675A5 JPWO2019197675A5 JP2020556304A JP2020556304A JPWO2019197675A5 JP WO2019197675 A5 JPWO2019197675 A5 JP WO2019197675A5 JP 2020556304 A JP2020556304 A JP 2020556304A JP 2020556304 A JP2020556304 A JP 2020556304A JP WO2019197675 A5 JPWO2019197675 A5 JP WO2019197675A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- identical amino
- lcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 228
- 230000003042 antagnostic Effects 0.000 description 61
- 239000005557 antagonist Substances 0.000 description 61
- 102000004965 antibodies Human genes 0.000 description 47
- 108090001123 antibodies Proteins 0.000 description 47
- 102100002977 CDR1 Human genes 0.000 description 40
- 239000000427 antigen Substances 0.000 description 33
- 102000038129 antigens Human genes 0.000 description 33
- 108091007172 antigens Proteins 0.000 description 33
- 102100009150 CLC Human genes 0.000 description 25
- 108060001645 CLC Proteins 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 208000006673 Asthma Diseases 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 101700044242 SER2 Proteins 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 201000003883 cystic fibrosis Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000002934 lysing Effects 0.000 description 2
- PQEJXGNZBLONLG-XJDOXCRVSA-N (2R)-2-amino-3-[1-[3-[2-[4-[1,3-bis(2-methoxyethylcarbamoyloxy)propan-2-yloxy]butanoylamino]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O PQEJXGNZBLONLG-XJDOXCRVSA-N 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 101710017803 At2g28720 Proteins 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 206010009839 Coeliac disease Diseases 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 210000003802 Sputum Anatomy 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002327 eosinophilic Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 102000006446 human galectin 10 Human genes 0.000 description 1
- 108091001378 human galectin 10 Proteins 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000001181 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806099.6A GB201806099D0 (en) | 2018-04-13 | 2018-04-13 | Galectin-10 Antibodies |
| GB1806099.6 | 2018-04-13 | ||
| GB1901648.4 | 2019-02-06 | ||
| GBGB1901648.4A GB201901648D0 (en) | 2019-02-06 | 2019-02-06 | Galectin-10 antibodies |
| PCT/EP2019/059570 WO2019197675A1 (en) | 2018-04-13 | 2019-04-12 | Galectin-10 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021520825A JP2021520825A (ja) | 2021-08-26 |
| JPWO2019197675A5 true JPWO2019197675A5 (pt) | 2022-04-20 |
Family
ID=66240109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556304A Pending JP2021520825A (ja) | 2018-04-13 | 2019-04-12 | ガレクチン−１０抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11066473B2 (pt) |
| EP (1) | EP3774905A1 (pt) |
| JP (1) | JP2021520825A (pt) |
| KR (1) | KR20210005070A (pt) |
| CN (1) | CN112166126A (pt) |
| AU (1) | AU2019250689A1 (pt) |
| BR (1) | BR112020020868A2 (pt) |
| CA (1) | CA3094215A1 (pt) |
| IL (1) | IL278010A (pt) |
| MX (1) | MX2020010821A (pt) |
| SG (1) | SG11202009140SA (pt) |
| WO (1) | WO2019197675A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019197675A1 (en) | 2018-04-13 | 2019-10-17 | Argenx Bvba | Galectin-10 antibodies |
| US11860114B2 (en) * | 2020-03-26 | 2024-01-02 | David Hurwitz | Determining atomic coordinates from X-ray diffraction data |
| US20230192865A1 (en) * | 2020-05-06 | 2023-06-22 | Cropedit Biotechnology Inc. | Nano antibody and use thereof |
| CN113667000B (zh) * | 2021-08-31 | 2022-08-19 | 中国医学科学院基础医学研究所 | 多肽在制备治疗2型免疫疾病的药物中的应用 |
| CN113666999B (zh) * | 2021-08-31 | 2022-08-19 | 中国医学科学院基础医学研究所 | 用于治疗2型免疫疾病的多肽 |
| CN113999287B (zh) * | 2021-12-02 | 2023-06-27 | 深圳湾实验室坪山生物医药研发转化中心 | 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途 |
| IL314365A (en) | 2022-01-18 | 2024-09-01 | argenx BV | Nebulization of antibody fragments |
| WO2023139107A1 (en) | 2022-01-18 | 2023-07-27 | argenx BV | Galectin-10 antibodies |
| WO2023150260A2 (en) * | 2022-02-03 | 2023-08-10 | Regents Of The University Of Minnesota | Compounds that target tem8, compositions, and methods |
| WO2023153496A1 (ja) * | 2022-02-10 | 2023-08-17 | 国立大学法人大阪大学 | 好酸球増多症又は気管支喘息バイオマーカー |
| CN115785245A (zh) * | 2022-07-18 | 2023-03-14 | 上海博满生物科技有限公司 | 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂 |
| CN115902204A (zh) * | 2022-09-23 | 2023-04-04 | 北京大学第三医院（北京大学第三临床医学院） | 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE10333406A1 (de) * | 2003-07-15 | 2005-02-10 | Protagen Ag | T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| CA3172682A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| CN106645752B (zh) * | 2016-12-27 | 2018-02-16 | 中南大学湘雅医院 | Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用 |
| WO2019197675A1 (en) | 2018-04-13 | 2019-10-17 | Argenx Bvba | Galectin-10 antibodies |
-
2019
- 2019-04-12 WO PCT/EP2019/059570 patent/WO2019197675A1/en unknown
- 2019-04-12 CA CA3094215A patent/CA3094215A1/en active Pending
- 2019-04-12 MX MX2020010821A patent/MX2020010821A/es unknown
- 2019-04-12 KR KR1020207032847A patent/KR20210005070A/ko not_active Application Discontinuation
- 2019-04-12 BR BR112020020868-0A patent/BR112020020868A2/pt active Search and Examination
- 2019-04-12 US US16/382,997 patent/US11066473B2/en active Active
- 2019-04-12 JP JP2020556304A patent/JP2021520825A/ja active Pending
- 2019-04-12 AU AU2019250689A patent/AU2019250689A1/en not_active Abandoned
- 2019-04-12 EP EP19718651.3A patent/EP3774905A1/en active Pending
- 2019-04-12 SG SG11202009140SA patent/SG11202009140SA/en unknown
- 2019-04-12 CN CN201980035738.2A patent/CN112166126A/zh active Pending
-
2020
- 2020-10-13 IL IL278010A patent/IL278010A/en unknown
-
2021
- 2021-03-08 US US17/194,950 patent/US11713354B2/en active Active
-
2023
- 2023-06-07 US US18/330,943 patent/US20240026010A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2434881C2 (ru) | Il-13 связывающие агенты | |
| US11713354B2 (en) | Galectin-10 antibodies | |
| CN103068846B9 (zh) | 包含二硫键稳定性Fv片段的双特异性抗体 | |
| JP2020528768A5 (pt) | ||
| CA2987118A1 (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2023134618A5 (pt) | ||
| RU2009107494A (ru) | АНТИТЕЛА К ErbB2 | |
| JP2014509861A5 (pt) | ||
| RU2006122037A (ru) | Новые анти-il 13 антитела и их использование | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2012525829A5 (pt) | ||
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JPWO2019197675A5 (pt) | ||
| JP2010524435A5 (pt) | ||
| JP2023093753A5 (pt) | ||
| US10975165B2 (en) | De-immunised anti-ERBB3 antibodies | |
| JPWO2021139777A5 (pt) | ||
| JP2019528046A5 (pt) | ||
| RU2017104638A (ru) | Нейтрализующие антитела к вирусу гриппа B и пути их применения | |
| RU2014123030A (ru) | Антагонистические антитела против человеческого рецептора гормона роста и способы их применения | |
| JP2015518368A5 (pt) | ||
| EP4257603A1 (en) | Pharmaceutical composition comprising anti-connective tissue growth factor antibody | |
| JPWO2022111425A5 (pt) | ||
| WO2022204244A1 (en) | Human ccl28 antibodies |